Description
Human MICA ELISA Kit
MICA is a cell-surface glycoprotein that is structurally similar to MHC class I. MICA plays a key role in governing the activation threshold of innate and adaptive arms of the immune system by presenting self-antigens to T cells. Thus MICA functions as a "tumor escape molecule" in that it presents antigens from tumors to T cells. MICA functions in a similar way as MHC class I, but unlike MICA, the MHC class I molecule is able to bind peptides only from cytosolic proteins. MICA functions to activate NK cells and T cells that express the NKG2D receptor to kill tumor cells. MICA also functions in natural killer (NK) cell-mediated cytotoxicity by triggering a non-conventional pathway of CTL activation. The Assay Genie MICA ELISA kit is a highly sensitive assay for the quantitative measurement of MICA in serum, blood, plasma, cell culture supernatant, and tissue samples.
Product Name: | Human MICA ELISA Kit |
Product Code: | HUFI00015 |
Size: | 96 Assays |
Alias: | MICA, MIC-A |
Detection method: | Sandwich ELISA, Double Antibody |
Application: | This immunoassay kit allows for the in vitro quantitative determination of Human MICA concentrations in serum plasma and other biological fluids. |
Sensitivity: | 46.875pg/ml |
Range: | 78.125-5000pg/ml |
Storage: | 4°C for 6 months |
Note: | For Research Use Only |
Recovery: | Matrices listed below were spiked with certain level of Human MICA and the recovery rates were calculated by comparing the measured value to the expected amount of Human MICA in samples. | ||||||||||||||||
| |||||||||||||||||
Linearity: | The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Human MICA and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. | ||||||||||||||||
| |||||||||||||||||
CV(%): | Intra-Assay: CV<8% Inter-Assay: CV<10% |
Component | Quantity | Storage |
ELISA Microplate (Dismountable) | 8×12 strips | 4°C for 6 months |
Lyophilized Standard | 2 | 4°C/-20°C |
Sample/Standard Dilution Buffer | 20ml | 4°C |
Biotin-labeled Antibody(Concentrated) | 120ul | 4°C (Protect from light) |
Antibody Dilution Buffer | 10ml | 4°C |
HRP-Streptavidin Conjugate(SABC) | 120ul | 4°C (Protect from light) |
SABC Dilution Buffer | 10ml | 4°C |
TMB Substrate | 10ml | 4°C (Protect from light) |
Stop Solution | 10ml | 4°C |
Wash Buffer(25X) | 30ml | 4°C |
Plate Sealer | 5 | - |
Other materials and equipment required:
- Microplate reader with 450 nm wavelength filter
- Multichannel Pipette, Pipette, microcentrifuge tubes and disposable pipette tips
- Incubator
- Deionized or distilled water
- Absorbent paper
- Buffer resevoir
Uniprot | Q29983 |
UniProt Protein Function: | MICA: Seems to have no role in antigen presentation. Acts as a stress-induced self-antigen that is recognized by gamma delta T- cells. Ligand for the KLRK1/NKG2D receptor. Binding to KLRK1 leads to cell lysis. Anti-MICA antibodies and ligand shedding are involved in the progression of monoclonal gammopathy of undetermined significance (MGUS)to multiple myeloma. Genetic variations in MICA may be a cause of susceptibility to psoriasis type 1 (PSORS1). Psoriasis is a common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. Genetic variation in MICA is a cause of susceptibility to psoriatic arthritis (PSORAS). PSORAS is an inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoidlike pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis). Belongs to the MHC class I family. MIC subfamily. 2 isoforms of the human protein are produced by alternative splicing. |
UniProt Protein Details: | Protein type:Membrane protein, integral Chromosomal Location of Human Ortholog: 6p21.33 Cellular Component: extracellular space; cell surface; integral to plasma membrane; cytoplasm Molecular Function:protein binding; beta-2-microglobulin binding; antigen binding; natural killer cell lectin-like receptor binding Biological Process: antigen processing and presentation; viral reproduction; natural killer cell mediated cytotoxicity; response to heat; cytolysis; defense response to bacterium; immune response to tumor cell; gamma-delta T cell activation; response to DNA damage stimulus; defense response to virus; T cell mediated cytotoxicity Disease: Psoriatic Arthritis, Susceptibility To; Psoriasis 1, Susceptibility To |
NCBI Summary: | This gene encodes the highly polymorphic major histocompatability complex class I chain-related protein A. The protein product is expressed on the cell surface, although unlike canonical class I molecules it does not seem to associate with beta-2-microglobulin. It is a ligand for the NKG2-D type II integral membrane protein receptor. The protein functions as a stress-induced antigen that is broadly recognized by intestinal epithelial gamma delta T cells. Variations in this gene have been associated with susceptibility to psoriasis 1 and psoriatic arthritis, and the shedding of MICA-related antibodies and ligands is involved in the progression from monoclonal gammopathy of undetermined significance to multiple myeloma. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jan 2014] |
UniProt Code: | Q29983 |
NCBI GenInfo Identifier: | 74740024 |
NCBI Gene ID: | 100507436 |
NCBI Accession: | Q29983.1 |
UniProt Related Accession: | Q29983 |
Molecular Weight: | |
NCBI Full Name: | MHC class I polypeptide-related sequence A |
NCBI Synonym Full Names: | MHC class I polypeptide-related sequence A |
NCBI Official Symbol: | MICA |
NCBI Official Synonym Symbols: | MIC-A; PERB11.1 |
NCBI Protein Information: | MHC class I polypeptide-related sequence A |
UniProt Protein Name: | MHC class I polypeptide-related sequence A |
Protein Family: | MICAL-like protein |
UniProt Gene Name: | MICA |
UniProt Entry Name: | MICA_HUMAN |
*Note: Protocols are specific to each batch/lot. For the correct instructions please follow the protocol included in your kit.
Before adding to wells, equilibrate the SABC working solution and TMB substrate for at least 30 min at 37 °C. When diluting samples and reagents, they must be mixed completely and evenly. It is recommended to plot a standard curve for each test.
Step | Protocol |
1. | Set standard, test sample and control (zero) wells on the pre-coated plate respectively, and then, record their positions. It is recommended to measure each standard and sample in duplicate. Wash plate 2 times before adding standard, sample and control (zero) wells! |
2. | Aliquot 0.1ml standard solutions into the standard wells. |
3. | Add 0.1 ml of Sample / Standard dilution buffer into the control (zero) well. |
4. | Add 0.1 ml of properly diluted sample ( Human serum, plasma, tissue homogenates and other biological fluids.) into test sample wells. |
5. | Seal the plate with a cover and incubate at 37 °C for 90 min. |
6. | Remove the cover and discard the plate content, clap the plate on the absorbent filter papers or other absorbent material. Do NOT let the wells completely dry at any time. Wash plate X2. |
7. | Add 0.1 ml of Biotin- detection antibody working solution into the above wells (standard, test sample & zero wells). Add the solution at the bottom of each well without touching the side wall. |
8. | Seal the plate with a cover and incubate at 37 °C for 60 min. |
9. | Remove the cover, and wash plate 3 times with Wash buffer. Let wash buffer rest in wells for 1 min between each wash. |
10. | Add 0.1 ml of SABC working solution into each well, cover the plate and incubate at 37 °C for 30 min. |
11. | Remove the cover and wash plate 5 times with Wash buffer, and each time let the wash buffer stay in the wells for 1-2 min. |
12. | Add 90 µL of TMB substrate into each well, cover the plate and incubate at 37 °C in dark within 10-20 min. (Note: This incubation time is for reference use only, the optimal time should be determined by end user.) And the shades of blue can be seen in the first 3-4 wells (with most concentrated standard solutions), the other wells show no obvious color. |
13. | Add 50 µL of Stop solution into each well and mix thoroughly. The color changes into yellow immediately. |
14. | Read the O.D. absorbance at 450 nm in a microplate reader immediately after adding the stop solution. |
When carrying out an ELISA assay it is important to prepare your samples in order to achieve the best possible results. Below we have a list of procedures for the preparation of samples for different sample types.
Sample Type | Protocol |
Serum | If using serum separator tubes, allow samples to clot for 30 minutes at room temperature. Centrifuge for 10 minutes at 1,000x g. Collect the serum fraction and assay promptly or aliquot and store the samples at -80°C. Avoid multiple freeze-thaw cycles. If serum separator tubes are not being used, allow samples to clot overnight at 2-8°C. Centrifuge for 10 minutes at 1,000x g. Remove serum and assay promptly or aliquot and store the samples at -80°C. Avoid multiple freeze-thaw cycles. |
Plasma | Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples at 4°C for 15 mins at 1000 × g within 30 mins of collection. Collect the plasma fraction and assay promptly or aliquot and store the samples at -80°C. Avoid multiple freeze-thaw cycles. Note: Over haemolysed samples are not suitable for use with this kit. |
Urine & Cerebrospinal Fluid | Collect the urine (mid-stream) in a sterile container, centrifuge for 20 mins at 2000-3000 rpm. Remove supernatant and assay immediately. If any precipitation is detected, repeat the centrifugation step. A similar protocol can be used for cerebrospinal fluid. |
Cell culture supernatant | Collect the cell culture media by pipette, followed by centrifugation at 4°C for 20 mins at 1500 rpm. Collect the clear supernatant and assay immediately. |
Cell lysates | Solubilize cells in lysis buffer and allow to sit on ice for 30 minutes. Centrifuge tubes at 14,000 x g for 5 minutes to remove insoluble material. Aliquot the supernatant into a new tube and discard the remaining whole cell extract. Quantify total protein concentration using a total protein assay. Assay immediately or aliquot and store at ≤ -20 °C. |
Tissue homogenates | The preparation of tissue homogenates will vary depending upon tissue type. Rinse tissue with 1X PBS to remove excess blood & homogenize in 20ml of 1X PBS (including protease inhibitors) and store overnight at ≤ -20°C. Two freeze-thaw cycles are required to break the cell membranes. To further disrupt the cell membranes you can sonicate the samples. Centrifuge homogenates for 5 mins at 5000xg. Remove the supernatant and assay immediately or aliquot and store at -20°C or -80°C. |
Tissue lysates | Rinse tissue with PBS, cut into 1-2 mm pieces, and homogenize with a tissue homogenizer in PBS. Add an equal volume of RIPA buffer containing protease inhibitors and lyse tissues at room temperature for 30 minutes with gentle agitation. Centrifuge to remove debris. Quantify total protein concentration using a total protein assay. Assay immediately or aliquot and store at ≤ -20 °C. |
Breast Milk | Collect milk samples and centrifuge at 10,000 x g for 60 min at 4°C. Aliquot the supernatant and assay. For long term use, store samples at -80°C. Minimize freeze/thaw cycles. |
Moran et al. | Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses | Pharmaceutics 2023 | PubMed ID: 36839682 |
Mylod et al. | Investigating the Susceptibility of Treatment-Resistant Oesophageal Tumours to Natural Killer Cell-Mediated Responses | Research Square 2022 |
Fill out our quote form below and a dedicated member of staff will get back to you within one working day!